Claudin 18.2 Inhibitor
Oct 27, 2026
Roche’s Divarasib Showcases Best-in-class Efficacy in Previously Treated KRAS G12C-mutated Lung Cancer; CLARITY-Gastric01 Shows 42% Lower Death Risk with Sonesitatug Vedotin; Lilly’s Olomorasib Shows Durable First-line Activity in KRAS G12C-mutant NSCLC; Izalontamab Brengitecan Doubles Median PFS in Phase 3 EGFR-Mutated NSCLC Trial; Novartis’ Remibrutinib Delivers Broad Disease Control with Consistent Safety in RMS
Roche’s Divarasib Sets a New Efficacy Benchmark in Previously Treated KRAS G12C-mutated Lung Cancer Roche reported pivotal findings from the Phase III KRASCENDO 1 trial, demonstrating that investigational divarasib, a next-generation KRAS G12C inhibitor, delivered superior efficacy compared with currently availa...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
